...
首页> 外文期刊>Histopathology: Official Journal of the British Division of the International Academy of Pathology >CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia.
【24h】

CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia.

机译:CK7 + / CK20-免疫表达谱是涎腺肿瘤的典型特征。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: To evaluate cytokeratin (CK) 7/20 expression patterns in salivary gland neoplasia. METHODS AND RESULTS: Formalin-fixed paraffin embedded tissue from 153 salivary gland tumours were evaluated for CK7/20 immunoreactivity. The tumours included pleomorphic adenoma (n = 24), myoepithelioma (n = 9), papillary cystadenoma (n = 3), oncocytoma (n = 2), adenoid cystic carcinoma (n = 22), mucoepidermoid carcinoma (n = 21), polymorphous low-grade adenocarcinoma (n = 21), carcinoma ex-pleomorphic adenoma (n = 11), acinic cell carcinoma (n = 17), epimyoepithelial carcinoma (n = 7), oncocytic carcinoma (n = 3), hyalinizing clear cell carcinoma (n = 1), papillary cystadenocarcinoma (n = 1), salivary duct carcinoma (n = 3), adenocarcinoma (not otherwise specified) (n = 4) and squamous carcinoma (n = 4). Immunohistochemical procedures were performed using monoclonal antibodies CK7 (OV-TL 12/30), CK20 (Ks 20.8) and M3515 cytokeratin (AE1/AE3) in the presence of appropriate controls. The results were expressed semiquantitatively, according to the estimated percentage of positive tumour cells: 1+, 5-25%; 2+, 26-75%; and 3+, 76-100%. All salivary gland neoplasms showed a CK7+/CK20- immunoprofile ranging from 5 to 100%. Squamous carcinoma showed negative CK7/20 immunoexpression. CONCLUSIONS: Although the CK7/20 immunoprofile is not useful in distinguishing the various types of salivary gland neoplasms or between benign and malignant salivary gland tumours, it may facilitate differentiation of primary salivary gland neoplasia from metastatic tumours and squamous carcinoma, and the diagnosis of metastatic salivary gland tumours.
机译:目的:评估唾液腺肿瘤中细胞角蛋白(CK)7/20的表达方式。方法和结果:对来自153例唾液腺肿瘤的福尔马林固定石蜡包埋组织进行了CK7 / 20免疫反应性评估。肿瘤包括多形性腺瘤(n = 24),肌上皮瘤(n = 9),乳头状膀胱腺瘤(n = 3),肿瘤细胞瘤(n = 2),腺样囊性癌(n = 22),粘液表皮样癌(n = 21),多形性低度腺癌(n = 21),癌前多形性腺瘤(n = 11),腺泡细胞癌(n = 17),上皮上皮癌(n = 7),吞噬细胞癌(n = 3),透明化透明细胞癌(n = 1),乳头状膀胱腺癌(n = 1),唾液管癌(n = 3),腺癌(未另作说明)(n = 4)和鳞状癌(n = 4)。在适当对照的情况下,使用单克隆抗体CK7(OV-TL 12/30),CK20(Ks 20.8)和M3515细胞角蛋白(AE1 / AE3)进行免疫组织化学程序。根据估计的阳性肿瘤细胞百分比,半定量表达结果:1 +,5-25%; 2 +,26-75%;和3 +,76-100%。所有唾液腺肿瘤均显示CK7 + / CK20-免疫分布范围为5%至100%。鳞癌显示CK7 / 20免疫表达阴性。结论:尽管CK7 / 20免疫谱不能用于区分各种类型的唾液腺肿瘤或良性和恶性唾液腺肿瘤,但它可能有助于区分原发性涎腺肿瘤与转移性肿瘤和鳞状细胞癌,并诊断转移性唾液腺肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号